NeuroSigma
- Company typePrivate
- Founded2011
- HeadquartersLos Angeles, United States
- Headcount1–10
- GTM typeB2C
- OfferingHardware or Manufacturing
NeuroSigma firmographics
Firmographics- Name
- NeuroSigma
- Legal name
- NeuroSigma, Inc.
- Website
- https://neurosigma.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
NeuroSigma industry classification
Industry- Product category
- Neuromodulation Medical Devices
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)
- akta.pro secondary industries
- Neurodevelopmental & Behavioral Therapy Platforms (ADHD/Autism/Behavioral Coaching) (HLALAEAJ), Child & Adolescent Behavioral Health Teletherapy Platforms (HLALAEAF), Neurology Telemedicine Platforms (HLALAGAC)
Keywords
Where NeuroSigma is headquartered
LocationHeadquarters
- HQ city
- Los Angeles
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
NeuroSigma business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Others
Revenue model
- Monarch eTNS Device Sales: NeuroSigma generates revenue from the sale of its Monarch eTNS medical device system for pediatric ADHD treatment. The device is available by prescription only. Pilot commercialization validated strong market demand with over 1,000 devices and 100,000 patches dispensed in the U.S. The second-generation device is scheduled for mass production and U.S. launch in Q1 2026.
- Patches and Consumables: Over 100,000 patches have been dispensed alongside Monarch eTNS devices, indicating a recurring consumables revenue stream associated with device usage.
- Licensing and Technology Licensing: NeuroSigma licenses its TNS technology to third parties, including a significant China licensing transaction with Ignis Therapeutics for ADHD applications (January 2022). The company is the exclusive worldwide licensee of UCLA's TNS intellectual property portfolio.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Monarch eTNS System (prescription device) |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
NeuroSigma product offering
Product offeringCore offering
NeuroSigma develops and commercializes the Monarch eTNS System, an FDA-cleared wearable medical device that delivers non-invasive external Trigeminal Nerve Stimulation (eTNS) for the treatment of pediatric ADHD in patients ages 7-12 who are not currently on prescription ADHD medications. The device is used at home during sleep under caregiver supervision, and the company also licenses its underlying TNS technology platform for additional neurological and psychiatric indications including epilepsy, depression, autism spectrum disorder, and PTSD.
Differentiator
Problem solved
Functional benefit
Brands
- Monarch eTNS System: The Monarch eTNS System is the company's flagship FDA-cleared medical device for treating pediatric ADHD. It is indicated as a monotherapy for patients ages 7 through 12 who are not currently taking prescription ADHD medications. The device uses external trigeminal nerve stimulation and is intended for use during sleep under caregiver supervision.
Products and services
- Monarch eTNS System The Monarch eTNS (external Trigeminal Nerve Stimulation) System is an FDA-cleared wearable medical device indicated as a monotherapy for treatment of pediatric Attention Deficit Hyperactivity Disorder (ADHD) in patients ages 7 through 12 years old who are not currently taking prescription ADHD medications. The device delivers gentle, external electrical pulses to stimulate the trigeminal nerve and is intended for home use during sleep under caregiver supervision.
- Monarch eTNS System (Second Generation) Second-generation Monarch eTNS System with improved design for treatment of pediatric ADHD. Received FDA clearance in January 2024 and officially launched in November 2025 following successful pilot commercialization. Manufactured by Armstrong Asia in Singapore, with high-volume manufacturing established via a December 2025 investment.
- Monarch eTNS Patches Disposable electrode patches used with the Monarch eTNS System during treatment sessions. Over 100,000 patches have been dispensed alongside devices during the pilot commercialization program, serving as a recurring consumables component of the system.
- TNS Technology Licensing Licensing of NeuroSigma's proprietary trigeminal nerve stimulation (TNS) technology platform to third parties for development and commercialization in specific indications and territories. Notable licensing transactions include a deal with Ignis Therapeutics for ADHD applications in China.
Quantifiable outcome
- ADHD symptom reduction demonstrated statistically significant on ADHD-RS scale in double-blind RCT (McGough et al., 2019)
- +4 more outcomes
Companies that use NeuroSigma
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
NeuroSigma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
NeuroSigma partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core, supporting and major.
- Armstrong AsiacoreArmstrong Asia, based in Singapore, serves as the manufacturing partner for NeuroSigma's second-generation Monarch eTNS device. This partnership enables high-volume scalable production of the device for pediatric ADHD treatment. First units expected to be delivered in March 2026. The manufacturing partnership was part of a $1 million investment led by Checkmate Capital.
- Data360supportingData360 is NeuroSigma's strategic digital marketing partner, providing digital marketing services to drive demand generation and customer acquisition for the Monarch eTNS System. Announced in January 2023.
- King's College LondonmajorKing's College London received MHRA approval to commence the largest clinical trial of eTNS for pediatric ADHD to date (April 2022). King's College London completed enrollment in a clinical trial of NeuroSigma's Monarch eTNS System for ADHD (January 2025). Early clinical experience with eTNS for epilepsy also conducted at King's College London.
- Ignis TherapeuticsmajorIgnis Therapeutics licensed NeuroSigma's eTNS technology for ADHD applications in China in a significant China licensing transaction. This represents a major international licensing deal that expands the geographic reach of NeuroSigma's TNS technology in the Chinese market.
- KT CorporationsupportingKT Corporation and NeuroSigma announced a strategic digital health partnership in June 2021, combining NeuroSigma's TNS technology with KT's digital health capabilities to explore collaborative opportunities in digital health solutions.
- UCLA (University of California, Los Angeles)coreTrigeminal nerve stimulation (TNS) was invented at UCLA, and NeuroSigma is the exclusive worldwide licensee of UCLA's intellectual property portfolio related to this technology. NeuroSigma conducts ongoing clinical research in collaboration with UCLA, including a clinical trial of Monarch eTNS for ADHD in children with fetal alcohol syndrome (announced April 2025).
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
NeuroSigma competitors and assessment
Company assessmentDirect peers
- electroCore: electroCore develops non-invasive vagus nerve stimulation (nVNS) devices such as gammaCore for headache and epilepsy indications. It is the most direct peer to NeuroSigma given its non-invasive external neurostimulation approach targeting overlapping neurologic conditions via a similar hardware-and-electrode model.
- Akili Interactive: Akili Interactive developed EndeavorRx, the first FDA-cleared prescription digital therapeutic for pediatric ADHD. It directly competes with NeuroSigma for the same patient population and prescriber channel with a non-drug alternative ADHD treatment, though delivered as software rather than hardware.
Broad incumbents
- LivaNova: LivaNova markets VNS Therapy, an implanted vagus nerve stimulation system for drug-resistant epilepsy and treatment-resistant depression. Comparable as an established neuromodulation incumbent targeting overlapping indications (epilepsy, depression) that NeuroSigma is pursuing non-invasively.
- NeuroPace: NeuroPace offers the RNS System, a closed-loop responsive neurostimulation implant for refractory epilepsy. Comparable as a neuromodulation company targeting drug-resistant epilepsy with FDA-cleared neurostim hardware, though using an invasive implanted device versus NeuroSigma's external approach.
- Inspire Medical Systems: Inspire Medical Systems commercializes an implantable neurostim device for obstructive sleep apnea. Comparable as a publicly traded neurostimulation hardware company with an FDA-cleared device treating a chronic neurologic/sleep condition via electrical stimulation.
- Medtronic: Medtronic operates one of the largest neuromodulation businesses globally, including deep brain stimulation, spinal cord stimulation, and targeted drug delivery systems. Comparable as a broad incumbent in implantable neurostimulation across overlapping conditions (epilepsy, movement disorders, psychiatric).
- Abbott: Abbott's Neuromodulation division offers Proclaim DRG, Infinity DBS, and Proclaim spinal cord stimulation systems for chronic pain and movement disorders. Comparable as a large incumbent with FDA-cleared neurostim hardware for chronic neurologic conditions.
- Boston Scientific: Boston Scientific operates a significant neuromodulation portfolio (Vercise DBS, WaveWriter spinal cord stim, Precision Spectra). Comparable as a broad medical device incumbent in implantable neurostimulation across chronic neurologic indications.
Emerging players
- Cognoa: Cognoa develops FDA-cleared diagnostic and therapeutic digital health products for pediatric neurodevelopmental conditions including autism. Comparable as a pediatric-focused neurodevelopmental technology company pursuing FDA pathways for childhood behavioral conditions, though in digital rather than neurostim hardware.
- Click Therapeutics: Click Therapeutics develops prescription digital therapeutics across CNS indications including ADHD and depression. Comparable as an emerging player pursuing FDA-cleared software-based treatments for the same neuropsychiatric conditions NeuroSigma targets with hardware.
Market position
Strengths5 records
Weaknesses1 record
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
NeuroSigma social profiles
Digital presenceNeuroSigma compliance and trust
Trust signalCompliance4 records
NeuroSigma financial estimates
Financial estimateRevenue estimate
Valuation estimate
NeuroSigma leadership team
Management profileNumber of profiles
Profiles7 records
NeuroSigma subsidiaries and ownership
Company hierarchySubsidiaries1 record
NeuroSigma funding detail
Funding detailFunding overview
Funding rounds5 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NeuroSigma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NeuroSigma
What does NeuroSigma do?
NeuroSigma develops and commercializes the Monarch eTNS System, an FDA-cleared wearable medical device that delivers non-invasive external Trigeminal Nerve Stimulation (eTNS) for the treatment of pediatric ADHD in patients ages 7-12 who are not currently on prescription ADHD medications. The device is used at home during sleep under caregiver supervision, and the company also licenses its underlying TNS technology platform for additional neurological and psychiatric indications including epilepsy, depression, autism spectrum disorder, and PTSD.
Is NeuroSigma a public or private company?
NeuroSigma is a private company. It is classified as venture growth investor backed and is currently operating.
When was NeuroSigma founded?
NeuroSigma was founded in 2011. It employs 1 to 10 people.
Where is NeuroSigma based?
NeuroSigma is headquartered in Los Angeles, United States, in the North America region.
How does NeuroSigma make money?
Three revenue lines are on record. Monarch eTNS Device Sales are the primary driver. The others are patches and Consumables and licensing and Technology Licensing.
Who are NeuroSigma's main competitors?
Direct peers on record are electroCore and Akili Interactive. Broad incumbents are LivaNova, NeuroPace, Inspire Medical Systems, Medtronic, Abbott and Boston Scientific. Emerging players are Cognoa and Click Therapeutics.
Does NeuroSigma have an API?
No public API is recorded for NeuroSigma.
What industry is NeuroSigma in?
NeuroSigma's product category is Neuromodulation Medical Devices. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables), with a secondary code of HLALAEAJ, Neurodevelopmental & Behavioral Therapy Platforms (ADHD/Autism/Behavioral Coaching). Its SIC code is 3845.